[Alpha blocker for protection against hypertensive target-organ damage].
Ebina
Toshiaki
T
Department of Medical Science and Cardiorenal Medicine, Postgraduate School of Medicine, Yokohama City University.
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001667:Binding, Competitive; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D000075202:Contraindications; D017292:Doxazosin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D050356:Lipid Metabolism; D009638:Norepinephrine / Q000378:metabolism; D017410:Practice Guidelines as Topic; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D018340:Receptors, Adrenergic, alpha-1; D017292:Doxazosin; D009638:Norepinephrine